Atlas Trials

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Clinical trial NCT06065540 · COMPLETED

Trial details

NCT number
NCT06065540
Sponsor
Novo Nordisk A/S
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Type 2 Diabetes Mellitus
Start date
2023-09-27
Primary completion
2025-11-19
Enrollment
2734

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.